CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

Valentina Boni,Howard A. Burris,Joyce F. Liu,Alexander I. Spira,Hendrik-Tobias Arkenau,Mary J. Fidler,Lee S. Rosen,Randy F. Sweis,Nataliya Volodymyrivna Uboha,Rachel E. Sanborn,Bert H. ONeil,James J. Harding,Patricia LoRusso,Amy Weise,Javier Garcia Corbacho,Iván Victoria,John W. Frye,Rachel Li,Mark Stroh,Funda Meric-Bernstam

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

2020

526Background: CX-2009 is a PROBODY drug conjugate (PDC) directed against CD166 (ALCAM) and conjugated to DM4, a potent microtubule inhibitor (MTI). CD166 is overexpressed in carcinomas but is also...

Keywords:

advanced cancer
ALCAM
Breast cancer
first in human
Drug
Pathology
in patient
Microtubule Inhibitor
Conjugate
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations